Compare Gilead Sciences, Inc. (GILD) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Zillow Group Inc Class A — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Zillow Group Inc Class A trades at $29.87 (market cap $6.59B). The key difference: Gilead Sciences, Inc. is far larger — about 27.7× Zillow Group Inc Class A's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Zillow Group Inc Class A for 86 Days on average.
| GILD | ZG | |
|---|---|---|
Market Cap | $182.40B | $6.59B |
Volume | 4,469,821 | 1,361,381 |
Sector | Health | Media |
52-Week High | $155.80 | $74.58 |
52-Week Low | $117.18 | $27.70 |
Typical Hold Time | 111 Days | 86 Days |
Enterprise Value | $205.46B | $6.47B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Zillow Group (ZG) trades at $29.90, up 6.9% in the last session, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growth to $2.58 billion in 2025 and a return to profitability with net income of $23 million. Recent earnings beats in Q1 and Q2 2026 suggest operational improvement, though cash flow trends remain volatile with negative net cash flow of $312 million in 2025.
The stock presents a compelling turnaround story with improving profitability and strong analyst price targets averaging $48.87, offering significant upside potential. However, investors face risks from the volatile housing market, high P/E ratio of 130, and ongoing competitive pressures in the real estate technology sector that could challenge future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
